Androgenetic Alopecia Management Strategies

Androgenetic alopecia, the most prevalent form of patterned hair loss in both men and women, arises from a complex interplay of genetic predisposition and androgenic hormones, chiefly dihydrotestosterone. Management strategies fall broadly into pharmacological, regenerative and physical categories. Pharmacological approaches include topical minoxidil and oral 5α-reductase inhibitors such as finasteride and dutasteride, which act to prolong anagen phase and reduce scalp dihydrotestosterone levels respectively. Regenerative medicine modalities harness autologous biologics, notably platelet-rich plasma and stem cell–derived therapies, to stimulate follicular stem cells and neovascularisation. Physical methods, particularly low-level laser therapy, employ photobiomodulation to enhance cellular proliferation in the hair follicle. Nutraceuticals and botanical extracts offer adjunctive benefits, while surgical interventions such as follicular unit transplantation remain the gold standard for advanced cases. Emerging directions include precision genetic risk prediction, combination regimens and standardisation of biologic preparation protocols. These strategies collectively aim to restore hair density, delay progression and improve patient well-being with an emphasis on safety and long-term efficacy.

Research from Nature Portfolio

Recent large-scale genomic investigations have refined our understanding of the hereditary architecture underlying androgenetic alopecia. Exome sequencing of tens of thousands of individuals has extended the allelic spectrum, uncovering novel rare-variant associations in genes linked to monogenic hair disorders and corroborating established loci involved in follicular development. Meanwhile, a genome-wide association study in over 70,000 men has identified 71 independent susceptibility loci that together explain a substantial fraction of familial risk. These loci illuminate biological pathways related to androgen metabolism, extracellular matrix remodelling and follicular stem cell regulation. Such insights not only enhance risk stratification models but also point to new molecular targets for therapeutic intervention, laying the groundwork for personalised management and the next generation of hair-restorative agents.

Androgenetic Alopecia Management Strategies publication trend

The graph below shows the total number of articles in androgenetic alopecia management strategies across all publications each year (not limited to Nature Index journals).

Technical terms

Androgenetic alopecia: A genetically influenced, androgen-driven form of patterned hair loss in adults.

Dihydrotestosterone (DHT): A potent androgen formed by 5α-reductase that contributes to follicular miniaturisation.

Platelet-rich plasma (PRP): An autologous concentration of platelets in plasma rich in growth factors used to stimulate tissue regeneration.

Low-level laser therapy (LLLT): Photobiomodulation using low-intensity lasers or light-emitting diodes to promote cellular activity in hair follicles.

Genome-wide association study (GWAS): A methodology for scanning markers across complete sets of DNA to identify genetic variants associated with a trait.

References

1. Analysis of 72,469 UK Biobank exomes links rare variants to male-pattern hair loss. Nature Communications (2023).
2. GWAS for male-pattern baldness identifies 71 susceptibility loci explaining 38% of the risk. Nature Communications (2017).
3. Regenerative medicine in the treatment of specific dermatologic disorders: a systematic review of randomized controlled clinical trials. Stem Cell Research & Therapy (2024).
4. Systematic Review of Platelet-Rich Plasma Use in Androgenetic Alopecia Compared with Minoxidil®, Finasteride®, and Adult Stem Cell-Based Therapy. International Journal of Molecular Sciences (2020).
5. Low-level laser therapy for the treatment of androgenetic alopecia in Thai men and women: a 24-week, randomized, double-blind, sham device-controlled trial. Lasers in Medical Science (2018).